Details

Autor(en) / Beteiligte

• Mehta, Rajendra H
• Leimberger, Jeffrey D
• van Diepen, Sean
• Meza, James
• Wang, Alice
• Jankowich, Rachael
• Harrison, Robert W
• Hay, Douglas
• Fremes, Stephen
• Duncan, Andra
• Soltesz, Edward G
• Luber, John
• Park, Soon
• Argenziano, Michael
• Murphy, Edward
• Marcel, Randy
• Kalavrouziotis, Dimitri
• Nagpal, Dave
• Bozinovski, John
• Toller, Wolfgang
• Heringlake, Matthias
• Goodman, Shaun G
• Levy, Jerrold H
• Harrington, Robert A
• Anstrom, Kevin J
• Alexander, John H

Titel

Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery

Ist Teil von

• The New England journal of medicine, 2017-05, Vol.376 (21), p.2032-2042

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• In this trial, 882 cardiac surgical patients with left ventricular dysfunction were assigned to levosimendan or placebo. There was no between-group difference in the rate of death, renal-replacement therapy, perioperative myocardial infarction, or mechanical cardiac assist device use. Cardiac surgery with the use of cardiopulmonary bypass is a common procedure, with more than 1 million operations performed annually in the United States and Europe. 1 Increasingly, patients who are referred for cardiac surgery are older and have multiple coexisting conditions, as compared with those who were referred for these procedures in the past. 2 These patients benefit from cardiac surgery but are at increased risk for perioperative complications that result in high morbidity and mortality and a high use of health care services. 2 – 4 One such complication, the low cardiac output syndrome, occurs in 3 to 14% of patients who . . .